First human test of experimental cancer drug halted
NCT ID NCT04240704
Summary
This was an early-stage study to test the safety and find the right dose of a new drug called JBH492. It involved 25 patients whose chronic lymphocytic leukemia or non-Hodgkin's lymphoma had returned or did not respond to previous treatments. The main goal was to see how much of the drug the body could handle and what side effects it caused, but the trial was later terminated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Helsinki, FIN-00029, Finland
-
Novartis Investigative Site
Dresden, 01307, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Chuo Ku, Tokyo, 104 0045, Japan
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
Conditions
Explore the condition pages connected to this study.